Stifel downgraded Biogen (NASDAQ: BIIB) from Buy to Hold and removed its price target (prior $451.00).
Thank you Snidely! I missed the option count! Still seems a good deal to buy @ 254 or less, given they have an approved and proven drug
From what I've read, this works out to $276/ share in 6 months. At current share price of $254 is a steal. That's 8.6% return for 6 months or 17.3% annualized.
I realize there is risk and time value of money is important, but this is a PROVEN drug and I think Risk vs Reward calls for stocking up a bit (cuse the pun)
As a Poster said below "Earnings will do nothing because they have no earnings. It will have to be merger news, or new test results."
It's the real deal.... great results on their Blood test... do your Homework...bioc is running to teens
Agreed. The Drs only need to draw blood NOT TISSUE
Why would this post get thumbs down? It's FACT
Must be some real angry idiots here
ASX the Aussie Stock exchange, the Home exchange for GTG which sells as GENE in the US in the for as ADRs.
How can you buy something without even understanding the share structure?
The US Shares are ADR (American Depositary Receipt) and are worth 150 shares on the Aussie exchange. Each Aussie Dollar is trading at $0.78.